Brownstein Hyatt Farber Schreck is pleased to announce that Steven Kazmierski has joined the firm’s Denver office as a shareholder in the Intellectual Property Department.
“We’re excited to welcome Steve to our IP team as we continue to expand our life sciences capabilities and talent,” said Airina Rodrigues, co-chair of the firm’s IP Department. “His postdoctoral experience in cell and molecular biology gives him a unique ability to help clients working at the forefront of life sciences and biotechnology and guide them through regulatory and policy challenges.”
A registered patent attorney with a strong scientific foundation, Kazmierski prepares and prosecutes complex patent applications and provides patent, licensing and enforcement counseling in biotechnology, chemistry and life sciences to help achieve clients’ business goals. He represents inventors, entrepreneurs, academic and research scientists, in-house counsel and technology transfer managers. His work includes preparing freedom-to-operate, infringement, validity and patentability opinions and performing intellectual property due diligence. He also manages patent portfolios and counsels clients on patent and Food and Drug Administration strategy.
Kazmierski prepares and prosecutes U.S. and international patents involving DNA and RNA technologies, protein and antibody engineering, biological and gene therapies. His patent work also extends to pharmaceuticals, drug conjugates, diagnostic assays and the underlying tools that power modern research. He frequently presents to corporate counsel, legal associations and academic conferences on topics including IP due diligence and patent eligibility.
Kazmierski earned his law degree from Washington University School of Law and his doctorate and bachelor’s degrees from Florida State University.